NIH HIV Research – Highlights at AIDS 2022

HIV.gov | August 15, 2022

Final Highlights from AIDS 2022: Reflections from ONAP Director Phillips, Ambassador Dr. Nkengasong, and ADM Levine

HIV.gov | August 3, 2022

Highlights from Day 4 of AIDS 2022: Reflections from Dr. Fauci and ADM Levine, Research Update, and Lessons from a Montreal Clinic

HIV.gov | August 2, 2022

Day 3 Highlights From AIDS 2022

IAC | 1 August 2022

Day 2 Highlights from AIDS 2022: Community Engagement, PEPFAR Lessons, and New HIV Viral Suppression Campaign

Highlights from Opening Day of AIDS 2022

HIV.gov | July 30, 2022

Lonely People With HIV Are More Likely to Skip Treatment

POZ Magazine | August 3, 2022

Smaller Volumes of 2 Brain Regions in Children Exposed to HIV in Utero

AIDS 2022, July 29-August 2, Montreal

Momentum builds to deliver long-acting PrEP for HIV prevention

Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084

Long-Acting CAB Maintains Superiority to TDF/FTC in Preventing HIV in Women

As AIDS2022 closes, UNAIDS urges world leaders to act with courage to end AIDS 

UNAIDS | August 2022

HIV in 2022 and beyond: A view from NIAID - non-adherence, disengagement from care, PrEP, vaccine - cure research

Courtesy NATAP (08/09/22)

An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy

Courtesy NATAP (08/03/22)

Association of prenatal PrEP exposure with neurodevelopmental and growth outcomes beyond 24 months among Kenyan children

Courtesy NATAP (08/09/22)

Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada

Courtesy NATAP (08/09/22)

Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study

Courtesy NATAP (08/09/22)

Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation

Courtesy NATAP (08/09/22)

Lp(a) in people living with HIV

Courtesy NATAP (08/01/22)

People With HIV Now Face Chronic Disease In Living Longer

Courtesy NATAP (07/29/22)

View on Targeted Violence, Being a Teen, Tied to PTSD in US MSM

Courtesy NATAP (08/03/22)

Different Factors Drive Mental Health Desires and Referrals for Black MSM

Courtesy NATAP (08/03/22)

Depression, Not Gender Identity, Tied to CVD Risk in US HIV+/HIV- Women

Courtesy NATAP (08/02/22)

Weight Gain After Antiretroviral Therapy Initiation in People Living with HIV

Courtesy NATAP (08/07/22)

Alcohol, Smoking, Drugs, Liver Disease-But Not TDF-Predict Fracture With HIV

Courtesy NATAP (08/07/22)

High Loneliness Score in Half of Ontario HIV Cohort-Tied to Poor ART Adherence

Courtesy NATAP (08/03/22)

Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study

Courtesy NATAP (08/09/22)

Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada

Courtesy NATAP (08/09/22)

Weight Gain After Non-nucleoside Reverse Transcriptase-to-Integrase Inhibitor Switch in the United States 

Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand

Age Associated with Comorbidites in Spain - Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years

Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy

Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years

Comorbidity Rate Rose 1% to 2% Yearly in 2008-2018 for HIV+ in Hospital Integrase Inhibitor in First ART Poses Some Cardio Risks in Big US Analysis

Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study

 Simulations for once weekly dosing of oral lenacapavir

AIDS 2022, July 29-August 2, Montreal

Lipid Parameters and Lipid-Modifying Agent Use in Participants Initiating F/TAF or F/TDF for PrEP in the DISCOVER Trial

Long-term Integrated Analysis of B/F/TAF in Treatment-Naïve Adults With HIV Through Five Years of Follow-up

AIDS 2022, July 29-August 2, Montreal

Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA)

Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study

AIDS 2022, July 29-August 2, Montreal

Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Yearsbr Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells

AIDS 2022, July 29-August 2, Montreal

Early Implementation and Clinical Outcomes of Long-Acting Injectable Cabotegravir and Rilpivirine in a Safety-Net Clinic

Courtesy NATAP (08/09/22)

Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy

Courtesy NATAP(08/09/22)

Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies

Courtesy NATAP (07/29/22)

Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study

Courtesy NATAP (08/02/22)

Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies Integrase Inhibitor in First ART Poses Some Cardio Risks in Big US Analysis

Courtesy NATAP (08/07/22)

Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis 

Real-World HIV Renal Outcomes With TDF to TAF Switch

Courtesy NATAP (07/29/22)

Meta-Analysis Confirms Higher COVID Death Risk With HIV

Courtesy NATAP (08/01/22)

HIV/HBV coinfection in pregnancy and response to antiretroviral therapy

Courtesy NATAP(08/09/22)

Current Pain, Black Race, Age Tied to Higher Frailty Risk With HIV in USn

Courtesy NATAP (08/07/22)

Arrests, City Stress, Life Events Tied to Suicide Attempts in Young With HIV

Courtesy NATAP (08/03/22)

Younger Age at Diagnosis of CVD and HTN With HIV Suggests Premature Aging

Courtesy NATAP (08/01/22)

Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam

Courtesy NATAP (08/03/22)

Integrated Screening/Diagnosis for Alcohol, Tobacco, Depression May Extend Life With HI

Courtesy NATAP (08/02/22)

Use of the Patient Generated Index to identify physical health challenges among people living with HIV 

Courtesy NATAP(08/09/22)

Arterial remodeling is associated with CD4 T cell count and plasma IL-10 in persons with HIV

Courtesy NATAP (08/08/22)

Can ART switch mitigate or reverse INSTI-related weight or BMI gain in high risk people living with HIV-1?

High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States

High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States 

Use of the Patient Generated Index to identify physical health challenges among people living with HIV

A propensity-score matched cohort study investigating premature age in people living with HIV

Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation

Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Years Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells 

"Give It a Shot": Best Practices From HCPs for Administering Long-Acting Cabotegravir + Rilpivirine

Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana

AIDS 2022, July 29-August 2, Montreal

Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084

AIDS 2022, July 29-August 2, Montreal

Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)

AIDS 2022, July 29-August 2, Montreal

Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies

Courtesy NATAP (07/29/22)